Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)
Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –
Spero Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Spero Therapeutics's pe ratio was 25.5× on Nov 11, 2026, against 19.0× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 25.5× | +11.2 |
| 2025 | Jan 31, 2025 | 14.3× | −2.9 |
| 2024 | Dec 31, 2024 | 17.2× | – |
See a number that looks wrong?